(12) **Translation of European patent specification**

(11) **NO/EP 3212637 B1**

(19) NO

NORWAY

(51) Int Cl.

C07D 403/12 (2006.01) ***C07D 403/14 (2006.01)***
A61K 31/4196 (2006.01) ***C07D 405/14 (2006.01)***
A61K 31/422 (2006.01) ***C07D 409/14 (2006.01)***
A61K 31/4412 (2006.01) ***C07D 413/14 (2006.01)***
A61P 25/12 (2006.01) ***C07D 417/14 (2006.01)***
C07D 401/14 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2021.08.02
(80)	Date of The European Patent Office Publication of the Granted Patent	2021.06.02
(86)	European Application Nr.	15790229.7
(86)	European Filing Date	2015.10.30
(87)	The European Application's Publication Date	2017.09.06
(30)	Priority	2014.10.31, GB, 201419430 2014.10.31, GB, 201419433
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
(73)	Proprietor	Indivior UK Limited, The Chapleo Building Henry Boot Way, Priory Park Hull HU4 7DY, Storbritannia
(72)	Inventor	CREMONESI, Susanna, Aptuit (Verona) Srl Via Alessandro Fleming 4, 37135 Verona, Italia MICHELI, Fabrizio, Aptuit (Verona) Srl Via Alessandro Fleming 4, 37135 Verona, Italia SEMERARO, Teresa, Aptuit (Verona) Srl Via Alessandro Fleming 4, 37135 Verona, Italia TARSI, Luca, Aptuit (Verona) Srl Via Alessandro Fleming 4, 37135 Verona, Italia
(74)	Agent or Attorney	Nordic Patent Service A/S, Bredgade 30, 1260 KØBENHAVN K, Danmark

(54) Title **DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS**

(56) References Cited:

WO-A2-2007/133561
WO-A1-2013/092893
WO-A1-03/091220
US-A- 3 654 305

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (http://worldwide.espacenet.com) or via the search engine on our website here: https://search.patentstyret.no/

Patentkrav

1. Forbindelse av formel (I) eller et farmasøytisk akseptabelt salt derav,



(I)

hvori

A er en mettet 3–6-leddet karbosyklisk ring og en slik ring kan være substituert med én eller flere C_{1-4}-alkylgrupper;

B er en mettet 4–6-leddet heterosyklisk ring, hvor ett eller to karbonatomer kan erstattes av et heteroatom valgt fra minst ett nitrogen eller et oksygen og det bindende atomet er alltid et nitrogenatom; en slik ring kan også være substituert ved karbonatomene, eller muligens ved et annet nitrogenatom, med én eller flere C_{1-4}-alkylgrupper;

G er fenyl, bifenyl, naftyl eller pyridyl, som eventuelt kan være substituert med 1, 2, 3, 4 eller 5 substituenter valgt fra gruppen som består av: halogen, cyano, hydroksyl, amino, C_{1-4}-alkylamino, C_{1-4}-alkyl, C_{1-4}-alkoksy, halogenC_{1-4}-alkyl, halogenC_{1-4}-alkoksy, SF_5, $C(=O)NH_2$ og $C(=O)(O)_zR_3$;

W er S, SO_2, O, CHR_2 eller NR_3;

n er 0 eller 1;

m er 1 eller 2;

p er 1 eller 2;

z er hver uavhengig 0 eller 1;

R er hydrogen eller C_{1-4}-alkyl; C_{1-4}-alkoksy;

R_1 er hver uavhengig hydrogen eller F, C_{1-4}-alkyl; OH, C_{1-4}-alkoksy;

R_2 er hver uavhengig hydrogen eller F, C_{1-4}-alkyl; OH, C_{1-4}-alkoksy;

R_3 er hver uavhengig hydrogen eller C_{1-4}-alkyl;

R_4 er hver uavhengig hydrogen eller C_{1-4}-alkyl; eller $-C(=O)C_{1-4}$-alkyl; $-C(=O)C_{1-4}$-alkoksyC_{1-4}-alkyl; $-C(=O)C_{3-6}$-sykloalkyl;

R_5 er hver uavhengig hydrogen eller C_{1-4}-alkyl;

R_6 er hver uavhengig hydrogen eller C_{1-4}-alkyl;

R_7 er hver uavhengig halogen, C_{1-4}-alkyl; OH, C_{1-4}-alkoksy;

G_1 er en 5–6-leddet heteroaromatisk gruppe som inneholder minst ett ringnitrogen, som eventuelt kan være substituert med 1, 2 eller 3 substituenter uavhengig valgt fra gruppen som består av: halogen, cyano, hydroksyl, amino, C_{1-4}-alkylamino, C_{1-4}-alkyl, halogenC_{1-4}-alkyl, halogenC_{1-4}-alkoksy, C_{1-4}-alkoksy, $C(=O)NH_2$ og $C(=O)(O)_zR_3$;

Y er fenyl eller en del valgt fra gruppen som består av: 5–6-leddet heteroaromatisk gruppe, en 8–11-leddet heteroaromatisk gruppe, en mettet mono-3–7-leddet karbosyklisk gruppe og en 8–11-leddet bisyklisk karbosyklisk gruppe, og for en hvilken som helst av slike grupper kan ett eller flere ringkarboner erstattes av $N(R_4)_z$,, O, S; en hvilken som helst av gruppene kan eventuelt substitueres med 1, 2 eller 3 substituenter valgt fra: halogen, cyano, hydroksyl, C_{1-4}-alkylamino, C_{1-4}-alkyl, C_{1-4}-alkoksy, halogenC_{1-4}-alkyl, halogenC_{1-4}-alkoksy, okso, -NHC(=O)C_{1-4}-alkyl, $-NR_5R_6$, SF_5, $-(CH_2)_zC(=O)NR_5R_6$, $-C(=O)(O)_zR_3$, -C_{1-4}-alkylCN, $-SO_2NR_5R_6$, Y' eller OY';

Y' er fenyl, eller en 5–6-leddet heteroaromatisk gruppe eventuelt substituert med 1 eller 2 R_7-grupper.

2. Forbindelse eller et farmasøytisk akseptabelt salt derav, ifølge krav 1, av formel (IA) der A og B av forbindelser av formel (I) er valgt fra følgende:



og hvori G, G_1, W, Y, n, m, p, z, R, R_1 og R_2 er som definert i krav 1.

3. Forbindelse eller et farmasøytisk akseptabelt salt derav, ifølge krav 1, av formel (IB) der A og B av forbindelser av formel (I) er valgt fra følgende:





og hvori G, G_1, W, Y, n, m, p, z, R, R_1 og R_2 er som definert i krav 1.

4. Forbindelse eller et farmasøytisk akseptabelt salt derav, ifølge krav 1, av formel (IIA)



(IIA)

hvori G, G_1, W, Y, n, m, p, z, R, R_1 og R_2 er som definert i krav 1.

5. Forbindelse eller et farmasøytisk akseptabelt salt derav, ifølge krav 1, av formel (IIB)



(IIB)

hvori G, G_1, W, Y, n, m, p, z, R, R_1 og R_2 er som definert i krav 1.

6. Forbindelse eller et farmasøytisk akseptabelt salt derav, ifølge et hvilket som helst av kravene 1 til 5, hvori W er S og R, R_1 og R_2 er hydrogen.

7. Forbindelse eller et farmasøytisk akseptabelt salt derav, ifølge et hvilket som helst av kravene 1 til 6, hvori G er fenyl eller pyridyl, eventuelt substituert med 1, 2, 3, 4 eller 5, for eksempel 1 eller 2, substituenter uavhengig valgt fra gruppen som består av: halogen, cyano, hydroksyl, amino, C_{1-4}-alkylamino, C_{1-4}-alkyl, halogenC_{1-4}-alkyl, halogenC_{1-4}-alkoksy, C_{1-4}-alkoksy, $-C(=O)NH_2$ og $-C(=O)(O)_zR_3$.

8. Forbindelse eller et farmasøytisk akseptabelt salt derav, ifølge et hvilket som helst av kravene 1 til 6, hvori G er fenyl eller pyridyl, eventuelt substituert med 1, 2 eller 3 grupper uavhengig valgt fra halogen, C_{1-4}-alkyl og halogenC_{1-4}-alkyl.

9. Forbindelse eller et farmasøytisk akseptabelt salt derav, ifølge et hvilket som helst av kravene 1 til 8, hvori G er valgt fra: fenyl, 4-trifluormetyl-fenyl, 2-fluor-4-trifluormetyl-fenyl, 2,4-difluorfenyl, 4-fluorfenyl, 2-trifluormetyl-fenyl, 2-trifluormetyl-4-fluorfenyl eller 3,5-diklorfenyl.

10. Forbindelse eller et farmasøytisk akseptabelt salt derav, ifølge et hvilket som helst av kravene 1 til 9, hvori G_1 er



hvori R_a er H eller C_{1-4}-alkyl; eventuelt hvori R_a er C_{1-4}-alkyl, for eksempel metyl.

11. Forbindelse eller et farmasøytisk akseptabelt salt derav, ifølge et hvilket som helst av kravene 1 til 10, hvori Y er valgt fra gruppen som består av:

• fenyl eventuelt substituert med én eller to substituenter valgt fra: cyano, $-C(=O)NH_2$, sulfonamid, acetyl, $-CH_2CN$, $-CH_2C(=O)NH_2$ og Y';

• en mettet mono-3–7-leddet karbosyklisk gruppe der 0 eller 1 eller 2 karbonatomer er erstattet av et heteroatom uavhengig valgt fra O eller NR_3;

• en 8–11-leddet bisyklisk karbosyklisk gruppe, eventuelt substituert med ett eller flere C_{1-4}-alkyl;

• en 5–6-leddet heteroaromatisk gruppe eventuelt substituert med én eller to substituenter valgt fra: halogen, cyano, hydroksyl, C_{1-4}-alkyl, halogenC_{1-4}-alkyl, C_{1-4}-alkoksy, $-(CH_2)_zC(=O)N(R_4R_5)$, Y' og OY';

• en 8–11-leddet heteroaromatisk gruppe der 1 eller 2 eller 3 atomkarboner kan erstattes av N, eventuelt substitueres med ett eller flere C_{1-4}-alkyl.

12. Forbindelse eller et farmasøytisk akseptabelt salt derav, ifølge et hvilket som helst av kravene 1 til 11, hvori Y er fenyl substituert med 1 eller 2 substituenter valgt fra

cyano,

$-CH_2CN$, $-C(=O)R_3$, $-(CH_2)_zC(=O)NR_5R_6$, $-SO_2NH_2$ og Y', hvori Y' er valgt fra oksadiazolyl, tetrazolyl, triazolyl og oksazolyl, der Y' eventuelt er substituert med C_{1-4}-alkyl; eventuelt er Y fenyl substituert med 1 substituent valgt fra cyano, CH_2CN, acetyl, $-CH_2C(=O)NH_2$, $-C(=O)NH_2$, $-SO_2NH_2$ og Y', hvori Y' er valgt fra oksadiazolyl, tetrazolyl, triazolyl og oksazolyl, der Y' eventuelt er substituert med metyl;

og hvori R_3, R_5, R_6 og z er som definert i krav 1.

13. Forbindelse eller et farmasøytisk akseptabelt salt derav, ifølge et hvilket som helst av kravene 1 til 12, hvori Y er valgt fra pyridyl, pyrimidinyl og pyrazinyl, hvilken som helst av disse gruppene kan eventuelt substitueres med 1 eller 2 substituenter valgt fra:

fluor, cyano, C_{1-4}-alkyl, C_{1-4}-alkoksy, halogenC_{1-4}-alkyl, og $-C(=O)NR_5R_6$; eventuelt hvori Y er pyridyl, eventuelt substituert med 1 eller 2 substituenter valgt fra: C_{1-4}-alkyl og $-C(=O)NH_2$;

hvori, R_5 og R_6 er som definert i krav 1.

14. Forbindelse eller et farmasøytisk akseptabelt salt derav, ifølge et hvilket som helst av kravene 1 til 13, hvori gruppe $-(CHR)_n(CR_1R_2)_m(CR_1R_2)_pW-$ er



15. Forbindelse, ifølge krav 1, valgt fra:

(1R,3R eller 1S,3S)-5-(3-{[4-metyl-5-(4-metyl-1,3-oksazol-5-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (Enantiomer 1);

(1R,3S/1S,3R)-5-(3-{[4-metyl-5-(4-metyl-1,3-oksazol-5-yl)-4H-1,2,4-triazol-3-yl]-sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS);

(1R,3S)-5-(3-{[4-metyl-5-(4-metyl-1,3-oksazol-5-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}-propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (Enantiomer 1);

(1R,3S)-5-(3-{[4-metyl-5-(4-metyl-1,3-oksazol-5-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}-propyl)-1-fenyl-5-azaspiro[2.4]heptan (Enantiomer 2);

(1R,3S)-5-(3-{[4-metyl-5-(4-metyl-1,3-oksazol-5-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}-propyl)-1-fenyl-5-azaspiro[2.4]heptan (Enantiomer 2);

(1R,3S/1S,3R)-1-[2-fluor-4-(trifluormetyl)fenyl]-5-(3-{[4-metyl-5-(4-metyl-1,3-oksazol-5-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-5-azaspiro[2.4]heptan (TRANS);

(1S,3R eller 1R,3S)-1-[2-fluor-4-(trifluormetyl)fenyl]-5-(3-{[4-metyl-5-(4-metyl-1,3-oksazol-5-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-5-azaspiro[2.4]heptan (Enantiomer 1);

(1R,3S eller 1S,3R)-1-[2-fluor-4-(trifluormetyl)fenyl]-5-(3-{[4-metyl-5-(4-metyl-1,3-oksazol-5-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-5-azaspiro[2.4]heptan (Enantiomer 2);

(1S,3S/1R,3R)-1-[2-fluor-4-(trifluormetyl)fenyl]-5-(3-{[4-metyl-5-(4-metyl-1,3-oksazol-5-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-5-azaspiro[2.4]heptan (CIS);

(1S,3S)-1-[2-fluor-4-(trifluormetyl)fenyl]-5-(3-{[4-metyl-5-(4-metyl-1,3-oksazol-5-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-5-azaspiro[2.4]heptan (Enantiomer 2);

(1S,3S/1R,3R)-1-(2,4-difluorfenyl)-5-(3-{[4-metyl-5-(4-metyl-1,3-oksazol-5-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-5-azaspiro[2.4]heptan (CIS);

(1S,3S)-1-(2,4-difluorfenyl)-5-(3-{[4-metyl-5-(4-metyl-1,3-oksazol-5-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-5-azaspiro[2.4]heptan (CIS, Enantiomer 2);

(1R,3S/1S,3R)-1-(4-fluorfenyl)-5-(3-{[4-metyl-5-(4-metyl-1,3-oksazol-5-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-5-azaspiro[2.4]heptan (CIS);

(1R,3S)-1-(4-fluorfenyl)-5-(3-{[4-metyl-5-(4-metyl-1,3-oksazol-5-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-5-azaspiro[2.4]heptan (CIS, Enantiomer 2);

(1S,3S/1R,3R)-5-(3-{[4-metyl-5-(4-metyl-1,3-oksazol-5-yl)-4H-1,2,4-triazol-3-yl]-sulfanyl}propyl)-1-[2-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (TRANS);

(1S,3S eller 1R,3R)-5-(3-{[4-metyl-5-(4-metyl-1,3-oksazol-5-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[2-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (TRANS, Enantiomer 2);

(1S,3R eller 1R,3S)-1-[4-fluor-2-(trifluormetyl)fenyl]-5-(3-{[4-metyl-5-(4-metyl-1,3-oksazol-5-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-5-azaspiro[2.4]heptan (CIS, Enantiomer 2);

(1S,3S eller 1R,3R)-1-[4-fluor-2-(trifluormetyl)fenyl]-5-(3-{[4-metyl-5-(4-metyl-1,3-oksazol-5-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-5-azaspiro[2.4]heptan (TRANS, Enantiomer 1);

(1S,3S/1R,3R)-1-(3,5-diklorfenyl)-5-(3-{[4-metyl-5-(4-metyl-1,3-oksazol-5-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-5-azaspiro[2.4]heptan (TRANS);

(1R,3S/1S,3R)-1-(3,5-diklorfenyl)-5-(3-{[4-metyl-5-(4-metyl-1,3-oksazol-5-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-5-azaspiro[2.4]heptan (CIS);

(1S,3S/1R,3R)-5-(3-{[4-metyl-5-(oksan-4-yl)-4H-1,2,4-triazol-3-yl]-sulfanyl}propyl)-¬1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (TRANS);

(1R,3R eller 1S,3S)-5-(3-{[4-metyl-5-(oksan-4-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (Enantiomer 1);

(1S,3S eller 1R,3R)-5-(3-{[4-metyl-5-(oksan-4-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (Enantiomer 2);

(1R,3S/1S,3R)-5-(3-{[4-metyl-5-(oksan-4-yl)-4H-1,2,4-triazol-3-yl]-sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS);

(1R,3S)-5-(3-{[4-metyl-5-(oksan-4-yl)-4H-1,2,4-triazol-3-yl]¬sulfanyl}¬propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (Enantiomer 1);

(1R,3S/1S,3R)-1-[2-fluor-4-(trifluormetyl)fenyl]-5-(3-{[4-metyl-5-(oksan-4-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-5-azaspiro[2.4]heptan (TRANS);

(1S,3R eller 1R,3S)-1-[2-fluor-4-(trifluormetyl)fenyl]-5-(3-{[4-metyl-5-(oksan-4-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-5-azaspiro[2.4]heptan (Enantiomer 1);

(1S,3S/1R,3R)-1-[2-fluor-4-(trifluormetyl)fenyl]-5-(3-{[4-metyl-5-(oksan-4-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-5-azaspiro[2.4]heptan (CIS);

(1S,3S)-1-[2-fluor-4-(trifluormetyl)fenyl]-5-(3-{[4-metyl-5-(oksan-4-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-5-azaspiro[2.4]heptan (Enantiomer 2);

(1R,3S/1S,3R)-5-{3-[(4-metyl-5-{8-oksabisyklo[3.2.1]oktan-3-yl}-4H-1,2,4-triazol-3-yl)sulfanyl]propyl}-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS);

(1R,3S)-5-{3-[(4-metyl-5-{8-oksabisyklo[3.2.1]oktan-3-yl}-4H-1,2,4-triazol-3-yl)-sulfanyl]propyl}-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (Enantiomer 1);

(1S,3S/1R,3R)-5-{3-[(5-sykloheksyl-4-metyl-4H-1,2,4-triazol-3-yl)sulfanyl]propyl}-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (TRANS);

(1R,3R eller 1S,3S)-5-{3-[(5-sykloheksyl-4-metyl-4H-1,2,4-triazol-3-yl)-sulfanyl]propyl}-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (Enantiomer 1);

(1S,3S eller 1R,3R)-5-{3-[(5-sykloheksyl-4-metyl-4H-1,2,4-triazol-3-yl)-sulfanyl]propyl}-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (Enantiomer 2);

(1R,3S/1S,3R)-5-{3-[(5-sykloheksyl-4-metyl-4H-1,2,4-triazol-3-yl)-sulfanyl]propyl}-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS);

(1R,3S)-5-{3-[(5-sykloheksyl-4-metyl-4H-1,2,4-triazol-3-yl)-sulfanyl]propyl}-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (Enantiomer 1);

1-{4-[4-metyl-5-({3-[(1R,3S/ 1S,R3)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan-5-yl]propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]piperidin-1-yl}etan-1-on (CIS);

1-{4-[4-metyl-5-({3-[(1R,3S)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan-5-yl]propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]piperidin-1-yl}etan-1-on (CIS, Enantiomer 1);

1-{4-[5-({3-[(1S,3S/1R,3R)-1-[2-fluor-4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan-5-yl]propyl}sulfanyl)-4-metyl-4H-1,2,4-triazol-3-yl]piperidin-1-yl}etan-1-on (CIS);

1-{4-[5-({3-[(1S,3S)-1-[2-fluor-4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan-5-yl]propyl}sulfanyl)-4-metyl-4H-1,2,4-triazol-3-yl]piperidin-1-yl}etan-1-on (CIS);

3-metoksy-1-{4-[4-metyl-5-({3-[(1R,3S)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]-heptan-5-yl]propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]piperidin-1-yl}propan-1-on (CIS, Enantiomer 1);

(1R,3S)-5-(3-{[5-(1-syklopropankarbonylpiperidin-4-yl)-4-metyl-4H-1,2,4-triazol-3-yl]-sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS, Enantiomer 1);

N-{4-[4-metyl-5-({3-[(1R,3S/1S,3R)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan-5-yl]propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]sykloheksyl}acetamid (CIS);

N-{4-[4-metyl-5-({3-[(1R,3S)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan-5-yl]propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]sykloheksyl}acetamid (CIS, Enantiomer 1);

(1R,3S/1S,3R)-5-(3-{[4-metyl-5-(morfolin-4-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS);

(1R,3S)-5-(3-{[4-metyl-5-(morfolin-4-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS, Enantiomer 1);

4-[4-metyl-5-({3-[(1R,3S)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan-5-yl]propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]piperidin-2-on (CIS, Enantiomer 1);

5-[4-metyl-5-({3-[(1R,3S)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan-5-yl]propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]piperidin-2-on (CIS, Enantiomer 1);

6-[4-metyl-5-({3-[(1R,3S/1S,3R)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan-5-yl]propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]-1,2-dihydropyridin-2-on (CIS);

5-[4-metyl-5-({3-[(1R,3S/1S,3R)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan-5-yl]propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]-1,2-dihydropyridin-2-on (CIS);

5-[4-metyl-5-({3-[(1R,3S)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan-5-yl]-propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]-1,2-dihydropyridin-2-on (CIS, Enantiomer 1);

5-[5-({3-[(1S,3S/1R,3R)-1-[2-fluor-4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan-5-yl]propyl}sulfanyl)-4-metyl-4H-1,2,4-triazol-3-yl]-1,2-dihydropyridin-2-on (CIS);

5-[5-({3-[(1S,3S/1R,3R)-1-(2,4-difluorfenyl)-5-azaspiro[2.4]heptan-5-yl]propyl}-sulfanyl)-4-metyl-4H-1,2,4-triazol-3-yl]-1,2-dihydropyridin-2-on (CIS);

5-[5-({3-[(1R,3S/1S,3R)-1-(4-fluorfenyl)-5-azaspiro[2.4]heptan-5-yl]propyl}sulfanyl)-4-metyl-4H-1,2,4-triazol-3-yl]-1,2-dihydropyridin-2-on (CIS);

5-[4-metyl-5-({3-[(1S,3S/1R,3R)-1-[2-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan-5-yl]propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]-1,2-dihydropyridin-2-on (TRANS);

1-metyl-5-[4-metyl-5-({3-[(1R,3S)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan-5-yl]propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]-1,2-dihydropyridin-2-on (CIS, Enantiomer 1);

4-[4-metyl-5-({3-[(1R,3S/1S,3R)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan-5-yl]propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]-1,2-dihydropyridin-2-on (CIS);

4-[4-metyl-5-({3-[(1S,3S/1R,3R)-1-[2-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan-5-yl]propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]-1,2-dihydropyridin-2-on (TRANS);

1-metyl-4-[4-metyl-5-({3-[(1R,3S)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan-5-yl]propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]-1,2-dihydropyridin-2-on (CIS, Enantiomer 1);

4-[5-({3-[(1S,3S)-1-[2-fluor-4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan-5-yl]-propyl}sulfanyl)-4-metyl-4H-1,2,4-triazol-3-yl]-1-metyl-1,2-dihydropyridin-2-on (CIS, Enantiomer 1);

(1S,3S/1R,3S)-5-(3-{[4-metyl-5-(pyridin-2-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (TRANS);

(1R,3S/1S,3R)-5-(3-{[4-metyl-5-(pyridin-2-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS);

(1R,3S/1S,3R)-5-(3-{[4-metyl-5-(pyridin-3-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS);

(1R,3S)-5-(3-{[4-metyl-5-(pyridin-3-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS, Enantiomer 2);

(1S,3S/1R,3R)-1-[2-fluor-4-(trifluormetyl)fenyl]-5-(3-{[4-metyl-5-(pyridin-3-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-5-azaspiro[2.4]heptan (CIS);

(1S,3S)-1-[2-fluor-4-(trifluormetyl)fenyl]-5-(3-{[4-metyl-5-(pyridin-3-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-5-azaspiro[2.4]heptan (CIS, Enantiomer 2);

(1S,3S/1R,3R)-1-(2,4-difluorfenyl)-5-(3-{[4-metyl-5-(pyridin-3-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-5-azaspiro[2.4]heptan (CIS);

(1S,3S)-1-(2,4-difluorfenyl)-5-(3-{[4-metyl-5-(pyridin-3-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-5-azaspiro[2.4]heptan (CIS, Enantiomer 2);

(1R,3S/1S,3R)-1-(4-fluorfenyl)-5-(3-{[4-metyl-5-(pyridin-3-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-5-azaspiro[2.4]heptan (CIS);

(1R,3S)-1-(4-fluorfenyl)-5-(3-{[4-metyl-5-(pyridin-3-yl)-4H-1,2,4-triazol-3-yl]-sulfanyl}propyl)-5-azaspiro[2.4]heptan (CIS, Enantiomer 2);

(1S,3S/1R,3R)-5-(3-{[4-metyl-5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (TRANS);

(1R,3S/1S,3R)-5-(3-{[4-metyl-5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS);

(1R,3S/1S,3R)-1-[2-fluor-4-(trifluormetyl)fenyl]-5-(3-{[4-metyl-5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-5-azaspiro[2.4]heptan (TRANS);

(1R,3S/1S,3R)-5-(3-{[4-metyl-5-(2-metylpyridin-3-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS);

(1R,3S)-5-(3-{[4-metyl-5-(2-metylpyridin-3-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS, Enantiomer 1);

(1S,3S/1R,3R)-5-(3-{[4-metyl-5-(2-metylpyridin-3-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[2-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (TRANS);

(1R,3S/1S,3R)-5-(3-{[4-metyl-5-(6-metylpyridin-3-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS);

(1R,3S)-5-(3-{[4-metyl-5-(3-metylpyridin-2-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS, Enantiomer 1);

(1R,3S)-5-(3-{[5-(2,6-dimetylpyridin-3-yl)-4-metyl-4H-1,2,4-triazol-3-yl]-sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS, Enantiomer 1);

(1R,3S/1S,3R)-5-(3-{[5-(2-fluorpyridin-3-yl)-4-metyl-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS);

(1R,3S)-5-[3-({4-metyl-5-[2-(trifluormetyl)pyridin-3-yl]-4H-1,2,4-triazol-3-yl}-sulfanyl)propyl]-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS, Enantiomer 1);

(1R,3S)-5-(3-{[5-(2-metoksypyridin-3-yl)-4-metyl-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS, Enantiomer 1);

(1R,3S)-5-(3-{[5-(2-metoksypyridin-3-yl)-4-metyl-4H-1 ,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS, Enantiomer 1);

5-[4-metyl-5-({3-[(1R,3S)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan-5-yl]propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]pyridin-2-karbonitril (CIS, Enantiomer 1);

4-[4-metyl-5-({3-[(1R,3S)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan-5-yl]-propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]pyridin-2-karbonitril (CIS, Enantiomer 1);

5-[4-metyl-5-({3-[(1S,3S/1R,3R)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan-5-yl]propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]pyridin-2-karboksamid (TRANS);

5-[4-metyl-5-({3-[(1S,3S eller 1R,3R)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan-5-yl]propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]pyridin-2-karboksamid (TRANS, Enantiomer 1);

5-[4-metyl-5-({3-[(1R,3R eller 1S,3S)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan-5-yl]propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]pyridin-2-karboksamid (TRANS, Enantiomer 2);

5-[4-metyl-5-({3-[(1R,3S/1S,3R)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan-5-yl]propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]pyridin-2-karboksamid (CIS);

5-[4-metyl-5-({3-[(1R,3S)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan-5-yl]-propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]pyridin-2-karboksamid (CIS, Enantiomer 1);

5-[5-({3-[(1S,3S)-1-[2-fluor-4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan-5-yl]propyl}sulfanyl)-4-metyl-4H-1,2,4-triazol-3-yl]pyridin-2-karboksamid (CIS, Enantiomer 1);

6-metyl-5-[4-metyl-5-({3-[(1R,3S)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan-5-yl]propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]pyridin-2-karboksamid (CIS, Enantiomer 1);

6-[4-metyl-5-({3-[(1R,3S)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan-5-yl]-propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]pyridin-3-karboksamid (CIS, Enantiomer 1);

6-[5-({3-[(1S,3S)-1-[2-fluor-4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan-5-yl]propyl}sulfanyl)-4-metyl-4H-1,2,4-triazol-3-yl]pyridin-3-karboksamid (CIS, Enantiomer 1);

4-[4-metyl-5-({3-[(1R,3S)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan-5-yl]-propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]pyridin-2-karboksamid (CIS, Enantiomer 1);

5-[4-metyl-5-({3-[(1R,3S)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan-5-yl]propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]pyridin-3-karboksamid (CIS, Enantiomer 1);

6-[4-metyl-5-({3-[(1R,3S)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan-5-yl]-propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]pyridin-2-karboksamid (CIS, Enantiomer 1);

N-metyl-6-[4-metyl-5-({3-[(1R,3S)-1-[4-(trifluormetyl)fenyl]-5-azaspiro-[2.4]heptan-5-yl]propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]pyridin-2-karboksamid (CIS, Enantiomer 1);

(1R,3S/1S,3R)-5-(3-{[4-metyl-5-(pyridazin-4-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS);

(1R,3S)-5-(3-{[4-metyl-5-(pyridazin-4-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS, Enantiomer 1);

(1S,3S/1R,3R)-5-(3-{[4-metyl-5-(pyrimidin-4-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (TRANS);

(1S,3S eller 1R,3R)-5-(3-{[4-metyl-5-(pyrimidin-4-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (TRANS, Enantiomer 1);

(1R,3R eller 1S,R3)-5-(3-{[4-metyl-5-(pyrimidin-4-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (TRANS, Enantiomer 2);

(1R,3S/1S,3R)-5-(3-{[4-metyl-5-(pyrimidin-4-yl)-4H-1 ,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS);

(1S,3S/1R,3R)-1-[2-fluor-4-(trifluormetyl)fenyl]-5-(3-{[4-metyl-5-(pyrimidin-4-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-5-azaspiro[2.4]heptan (CIS);

(1S,3S eller 1R,3R)-5-(3-{[4-metyl-5-(pyrazin-2-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (TRANS, Enantiomer 1);

(1R,3R eller 1S,R3)-5-(3-{[4-metyl-5-(pyrazin-2-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (TRANS, Enantiomer 2);

(1R,3S/1S,3R)-5-(3-{[4-metyl-5-(pyrazin-2-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS);

(1R,3S)-5-(3-{[4-metyl-5-(pyrazin-2-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS, Enantiomer 2);

(1S,3S/1R,3R)-1-[2-fluor-4-(trifluormetyl)fenyl]-5-(3-{[4-metyl-5-(pyrazin-2-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-5-azaspiro[2.4]heptan (CIS);

(1R,3S/1S,3R)-5-(3-{[4-metyl-5-(6-metylpyrazin-2-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS);

(1R,3S/1S,3R)-5-(3-{[4-metyl-5-(5-metylpyrazin-2-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS);

(1R,3S/1S,3R)-5-(3-{[4-metyl-5-(3-metylpyrazin-2-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS);

(1R,3S)-5-(3-{[4-metyl-5-(3-metylpyrazin-2-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS, Enantiomer 2);

5-[4-metyl-5-({3-[(1R,3S)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan-5-yl]propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]pyrazin-2-karboksamid (CIS);

(1R,3S/1S,3R)-5-(3-{[4-metyl-5-(3-metyl-1,2-oksazol-5-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS);

(1R,3S)-5-(3-{[4-metyl-5-(3-metyl-1,2-oksazol-5-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}-propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS, Enantiomer 1);

(1R,3S/1S,3R)-5-(3-{[4-metyl-5-(4-metyl-1,3-tiazol-5-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS);

(1R,3S)-5-(3-{[4-metyl-5-(4-metyl-1,3-tiazol-5-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}-propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS, Enantiomer 1);

(1R,3S/1S,3R)-5-(3-{[4-metyl-5-(1,3-tiazol-2-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS);

(1R,3S)-5-(3-{[4-metyl-5-(1,3-tiazol-2-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS, Enantiomer 1);

(1R,3S/1S,3R)5-(3-{[4-metyl-5-(1-metyl-1H-pyrazol-4-yl)-4H-1,2,4-triazol-3-yl]-sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS);

(1R,3S)-5-(3-{[4-metyl-5-(1-metyl-1H-pyrazol-4-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}-propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS, Enantiomer 2);

(1R,3S/1S,3R)-5-(3-{[4-metyl-5-(1-metyl-1H-pyrazol-5-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS);

(1R,3S)-5-(3-{[4-metyl-5-(1-metyl-1H-pyrazol-5-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}-propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS, Enantiomer 2);

(1R,3S/1S,3R)-5-(3-{[5-(furan-2-yl)-4-metyl-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS);

(1R,3S/1S,3R)-5-(3-{[5-(furan-3-yl)-4-metyl-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS);

(1R,3S/1S,3R)-5-(3-{[4-metyl-5-(tiofen-2-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS);

(1R,3S/1S,3R)-5-(3-{[4-metyl-5-(tiofen-3-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS);

(1R,3S/1S,3R)-5-(3-{[4-metyl-5-(1-metyl-1H-pyrrol-2-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS);

(1S,3S/1R,3R)-5-(3-{[4-metyl-5-(1,2,3-tiadiazol-4-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (TRANS);

(1R,3S/1S,3R)-5-(3-{[4-metyl-5-(1,2,3-tiadiazol-4-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS);

(1R,3S)-5-(3-{[4-metyl-5-(1,2,3-tiadiazol-4-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS, Enantiomer 1);

(1R,3S)-5-(3-{[4-metyl-5-(4-metyl-1,2,3-tiadiazol-5-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}-propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS, Enantiomer 1);

(1R,3S)-5-[3-({4-metyl-5-[2-(pyridin-3-yl)-1,3-oksazol-5-yl]-4H-1,2,4-triazol-3-yl}-sulfanyl)propyl]-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS, Enantiomer 1);

(1R,3S)-5-(3-{[4-metyl-5-(6-fenoksypyridin-3-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS, Enantiomer 1);

(1R,3S)-5-{3-[(4-metyl-5-{[1,2,4]triazolo[4,3-a]pyridin-6-yl}-4H-1,2,4-triazol-3-yl)-sulfanyl]propyl}-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS, Enantiomer 1);

(1R,3S)-5-{3-[(4-metyl-5-{[1,2,4]triazolo[4,3-a]pyridin-7-yl}-4H-1,2,4-triazol-3-yl)-sulfanyl]propyl}-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS, Enantiomer 1);

(1S,3S)-1-[2-fluor-4-(trifluormetyl)fenyl]-5-{3-[(4-metyl-5-{[1,2,4]triazolo[4,3-a]-pyridin-7-yl}-4H-1,2,4-triazol-3-yl)sulfanyl]propyl}-5-azaspiro[2.4]heptan (CIS, Enantiomer 1);

(1R,3S)-5-{3-[(4-metyl-5-{3-metyl-[1,2,4]triazolo[4,3-a]pyridin-6-yl}-4H-1,2,4-triazol-3-yl)sulfanyl]propyl}-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS, Enantiomer 1);

(1R,3S)-5-{3-[(5-{1H-imidazo[4,5-b]pyridin-5-yl}-4-metyl-4H-1,2,4-triazol-3-yl)-sulfanyl]propyl}-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS, Enantiomer 1);

(1R,3S)-5-[3-({4-metyl-5-[4-(1H-1,2,3,4-tetrazol-5-yl)fenyl]-4H-1,2,4-triazol-3-yl}-sulfanyl)propyl]-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS, Enantiomer 1);

(1R,3S)-5-[3-({4-metyl-5-[4-(1,3,4-oksadiazol-2-yl)fenyl]-4H-1,2,4-triazol-3-yl}-sulfanyl)propyl]-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS, Enantiomer 1);

(1R,3S)-5-[3-({4-metyl-5-[4-(5-metyl-1,2,4-oksadiazol-3-yl)fenyl]-4H-1,2,4-triazol-3-yl}sulfanyl)propyl]-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS, Enantiomer 1);

(1R,3S)-5-[3-({4-metyl-5-[4-(4H-1,2,4-triazol-4-yl)fenyl]-4H-1,2,4-triazol-3-yl}sulfanyl)propyl]-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS, Enantiomer 1);

(1R,3S)-5-[3-({4-metyl-5-[4-(1,3-oksazol-2-yl)fenyl]-4H-1,2,4-triazol-3-yl}sulfanyl)-propyl]-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS, Enantiomer 1);

(1R,3S)-5-[3-({4-metyl-5-[3-(1,3-oksazol-2-yl)fenyl]-4H-1,2,4-triazol-3-yl}-sulfanyl)propyl]-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS, Enantiomer 1);

4-[4-metyl-5-({3-[(1R,3S)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan-5-yl]-propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]benzamid (CIS, Enantiomer 1);

4-[4-metyl-5-({3-[(1R,3S)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan-5-yl]-propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]benzonitril (CIS, Enantiomer 1);

1-{4-[4-metyl-5-({3-[(1R,3S)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan-5-yl]-propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]fenyl}etan-1-on (CIS, Enantiomer 1);

4-[4-metyl-5-({3-[(1R,3S)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan-5-yl]-propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]benzen-1-sulfonamid (CIS, Enantiomer 1);

2-{4-[4-metyl-5-({3-[(1R,3S)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan-5-yl]-propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]fenyl}acetonitril (CIS, Enantiomer 1);

2-{4-[4-metyl-5-({3-[(1R,3S)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan-5-yl]-propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]fenyl}acetamid (CIS, Enantiomer 1);

3-[4-metyl-5-({3-[(1R,3S)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan-5-yl]-propyl}sulfanyl)-4H-1,2,4-triazol-3-yl]benzamid (CIS, Enantiomer 1);

(1S,3S)-1-[2-fluor-4-(trifluormetyl)-fenyl]-5-{4-[4-metyl-5-(oksan-4-yl)-4H-1,2,4-triazol-3-yl]butyl}-5-azaspiro[2.4]¬heptan (Enantiomer 2);

(1R,3S)-5-{4-[4-metyl-5-(4-metyl-1,3-oksazol-5-yl)-4H-1,2,4-triazol-3-yl]butyl}-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.4]heptan (CIS, Enantiomer 1);

(1R,3S/1S,3R)-5-(3-{[4-metyl-5-(4-metyl-1,3-oksazol-5-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.5]oktan (TRANS);

(1S,3R eller 1R,3S)-5-(3-{[4-metyl-5-(4-metyl-1,3-oksazol-5-yl)-4H-1,2,4-triazol-3-yl]-sulfanyl}propyl)-1-[4-(trifluormetyl)fenyl]-5-azaspiro[2.5]oktan (TRANS, Enantiomer 2);

eller et farmasøytisk akseptabelt salt derav.

16. Forbindelse ifølge krav 1 som har formelen:



;


;


;


;


;



;

eller



;

eller et farmasøytisk akseptabelt salt derav.

17. Forbindelse ifølge krav 1 som har formelen:



;



;



;


;


;


;


;

eller



;

eller et farmasøytisk akseptabelt salt derav.

18. Farmasøytisk sammensetning omfattende en forbindelse ifølge et hvilket som helst av kravene 1–17 og en farmasøytisk akseptabel bærer.

19. Forbindelse ifølge et hvilket som helst av kravene 1 til 17 for anvendelse som et medikament.

20. Forbindelse ifølge et hvilket som helst av kravene 1–17 for anvendelse ved behandling av en tilstand, hvori tilstanden er valgt fra:

(i) stoffmisbruk, eventuelt hvori stoffmisbruket er alkohol-, kokain-, heroin- eller nikotinmisbruk; eller

(ii) en dyskinetisk lidelse, eventuelt hvori den dyskinetiske lidelsen er Parkinsons sykdom, nevroleptisk indusert parkinsonisme eller tardive dyskinesier; eller

(iii) kognitiv svikt, eventuelt hvori den kognitive svikten er en hukommelsesforstyrrelse eller Alzheimers sykdom; eller

(iv) depresjon, angst, en spiseforstyrrelse, seksuell dysfunksjon, for tidlig utløsning, en søvnforstyrrelse, oppkast, en bevegelsesforstyrrelse, en obsessiv-kompulsiv lidelse, amnesi, aggresjon, autisme, svimmelhet, demens, en døgnrytmeforstyrrelse, eller en gastrisk motilitetsforstyrrelse, eventuelt hvori den gastriske motilitetsforstyrrelsen er IBS; eller

(v) en psykotisk tilstand, eventuelt hvori den psykotiske tilstanden er schizofreni, en schizo-affektiv lidelse, psykotisk depresjon, mani, paranoid forstyrrelse eller en paranoid personlighetsforstyrrelse; eller

(vi) medikamentavhengighet, abstinenssymptomer fra legemidler med misbruk eller inhibering av toleranse indusert av opioider, eventuelt hvori legemidlet er alkohol, kokain, et opiat, nikotin eller et benzodiazepin; eller

(vii) ikke-substansrelaterte lidelser og vanedannende lidelser, eventuelt hvori lidelsen er en spillesykdom.